Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Blood

Volumn 125, Issue 23, 2015, Pages 3618-3626

  Selimoglu Buet, Dorothée ^a,b   Wagner Ballon, Orianne ^c,d   Saada, Véronique ^e   Bardet, Valérie ^f,g   Itzykson, Raphaël ^a,h   Bencheikh, Laura ^a,b   Morabito, Margot ^a   Met, Elisabeth ^a   Debord, Camille ^f,g   Benayoun, Emmanuel ^c,d   Nloga, Anne Marie ^h   Fenaux, Pierre ^h   Braun, Thorsten ⁱ   Willekens, Christophe ^e   Quesnel, Bruno ^j,k,l   Adès, Lionel ^h   Fontenay, Michaela ^f,g   Rameau, Philippe ^m   Droin, Nathalie ^a,m   Koscielny, Serge ^e   Solary, Eric ^a,b   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d FACULTÉ DE MÉDECINE   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f INSTITUT COCHIN   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j UNIV LILLE   (France)

^k JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m CNRS UMS3655   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; FC RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CELL FRACTIONATION; CELL POPULATION; CELL SELECTION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HEMATOLOGICAL PARAMETERS; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MONOCYTE SUBSET REPARTITION; MONOCYTOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; BLOOD; CLINICAL TRIAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD14; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, IGG; SENSITIVITY AND SPECIFICITY;

EID: 84930960514     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-620781     Document Type: Article

References (53)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
2. Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27(7):1441-1450.
3. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74-e80.
4. Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33(3):375-386.
5. Wong KL, Tai JJ-Y, Wong W-C, et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011;118(5):e16-e31.
6. Zawada AM, Rogacev KS, Rotter B, et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood. 2011;118(12):e50-e61.
7. Yona S, Jung S. Monocytes: subsets, origins, fates and functions. Curr Opin Hematol. 2010; 17(1):53-59.
8. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19(1):71-82.
9. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669-692.
10. Lauvau G, Chorro L, Spaulding E, Soudja SM. Inflammatory monocyte effector mechanisms. Cell Immunol. 2014;291(1-2):32-40.
11. Frankenberger M, Sternsdorf T, Pechumer H, Pforte A, Ziegler-Heitbrock HW. Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis. Blood. 1996;87(1):373-377.
12. Belge K-U, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002;168(7):3536-3542.
13. Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005-3015.
14. Braun T, Itzykson R, Renneville A, et al Groupe Francophone des Myélodysplasies. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118(14):3824-3831.
15. van de Loosdrecht AA, Alhan C, Béné MC, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009;94(8):1124-1134.
16. Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26(7):1730-1741.
17. Droin N, Jacquel A, Hendra J-B, et al. Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. Blood. 2010;115(1):78-88.
18. Qiu P, Simonds EF, Bendall SC, et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol. 2011;29(10):886-891.
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-845.
20. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428-2436.
21. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122(25):4021-4034.
22. Storniolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia. 1990;4(11):766-770.
23. Ancuta P, Liu K-Y, Misra V, et al. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16-monocyte subsets. BMC Genomics. 2009;10:403.
24. Rogacev KS, Cremers B, Zawada AM, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol. 2012;60(16):1512-1520.
25. Tapp LD, Shantsila E, Wrigley BJ, Pamukcu B, Lip GYH. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost. 2012;10(7):1231-1241.
26. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010; 327(5966):656-661.
27. Hanna RN, Shaked I, Hubbeling HG, et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ Res. 2012;110(3):416-427.
28. Etzrodt M, Cortez-Retamozo V, Newton A, et al. Regulation of monocyte functional heterogeneity by miR-146a and Relb. Cell Reports. 2012;1(4):317-324.
29. Wong KL, Yeap WH, Tai JJY, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. Immunol Res. 2012;53(1-3):41-57.
30. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum. 2012;64(3):671-677.
31. Fingerle G, Pforte A, Passlick B, Blumenstein M, Ströbel M, Ziegler-Heitbrock HW. The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. Blood. 1993;82(10):3170-3176.
32. Skrzeczyñska J, Kobylarz K, Hartwich Z, Zembala M, Pryjma J. CD14+CD16+ monocytes in the course of sepsis in neonates and small children: monitoring and functional studies. Scand J Immunol. 2002;55(6):629-638.
33. Soares G, Barral A, Costa JM, Barral-Netto M, Van Weyenbergh J. CD16+ monocytes in human cutaneous leishmaniasis: increased ex vivo levels and correlation with clinical data. J Leukoc Biol. 2006;79(1):36-39.
34. Pilette C, Francis JN, Till SJ, Durham SR. CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge. Eur Respir J. 2004;23(6):876-884.
35. Tallone T, Turconi G, Soldati G, Pedrazzini G, Moccetti T, Vassalli G. Heterogeneity of human monocytes: an optimized four-color flow cytometry protocol for analysis of monocyte subsets. J Cardiovasc Transl Res. 2011;4(2):211-219.
36. Siedlar M, Strach M, Bukowska-Strakova K, et al. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD161+ monocytes in common variable immunodeficiency (CVID) patients. Clin Immunol. 2011;139(2):122-132.
37. Korkosz M, Bukowska-Strakova K, Sadis S, Grodzicki T, Siedlar M. Monoclonal antibodies against macrophage colony-stimulating factor diminish the number of circulating intermediate and nonclassical (CD14(++)CD16(+)/CD14(+) CD16(++)) monocytes in rheumatoid arthritis patient. Blood. 2012;119(22):5329-5330.
38. Huizinga TW, van der Schoot CE, Jost C, et al. The PI-linked receptor FcRIII is released on stimulation of neutrophils. Nature. 1988;333(6174):667-669.
39. de Haas M, Kleijer M, van Zwieten R, Roos D, von dem Borne AE. Neutrophil Fc gamma RIIIb deficiency, nature, and clinical consequences: a study of 21 individuals from 14 families. Blood. 1995;86(6):2403-2413.
40. Moulding DA, Hart CA, Edwards SW. Regulation of neutrophil FcgammaRIIIb (CD16) surface expression following delayed apoptosis in response to GM-CSF and sodium butyrate. J Leukoc Biol. 1999;65(6):875-882.
41. Hanna RN, Carlin LM, Hubbeling HG, et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C-monocytes. Nat Immunol. 2011;12(8):778-785.
42. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102(1):394-403.
43. Gorczyca W. Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukemia (AML-M5), acute myelomonocytic leukemia (AML-M4), and chronic myelomonocytic leukemia (CMML). Methods Cell Biol. 2004;75:665-677.
44. Lacronique-Gazaille C, Chaury M-P, Le Guyader A, Faucher JL, Bordessoule D, Feuillard J. A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica. 2007;92(6):859-860.
45. SubiráD, Font P, Villalón L, et al. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders? Transl Res. 2008;151(5):240-245.
46. Dunphy CH. Comparative analysis of detecting monocytic cells and their aberrancy. Appl Immunohistochem Mol Morphol. 2011;19(4): 336-340.
47. Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol. 2010;23(3):379-390.
48. Shen Q, Ouyang J, Tang G, et al. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response [published online ahead of print October 30, 2014]. Eur J Haematol.
49. Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol. 2005;124(5):799-806.
50. Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124(9):1513-1521.
51. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114(16):3448-3458.
52. Meldi K, Tingting Q, Buchi F, et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia [published online ahead of print March 30, 2015]. J Clin Invest. doi: 10.1172/JCI78752.
53. Aucagne R, Droin N, Paggetti J, et al. Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J. Clin. Invest. 2011; 121(6):2361-2370.